To add Benzinga News as your preferred source on Google, click here .Here are some other stocks moving in pre-market trading.Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market trading after the company reported the FDA approval of BYSANTI™ (milsaperidone) for the treatment of bipolar I disorder and schizophrenia – a new chemical entity opening new horizons in psychiatric innovation. ...

Core Viewpoint - Novo Nordisk's stock experienced a decline of over 10% following the announcement that its next-generation weight loss drug, CagriSema, did not meet its primary target of non-inferiority in weight loss compared to Eli Lilly's drug, tirzepatide, after 84 weeks [1] Group 1 - CagriSema failed to achieve its primary endpoint in the clinical trial [1] - Eli Lilly's stock saw an increase of 2.1% in premarket trading as a result of Novo Nordisk's announcement [1] - Novo Nordisk is considering additional trials for CagriSema, including testing higher-dose combinations [1]

Group 1 - Novo Nordisk's experimental obesity drug CagriSema did not meet the primary endpoint in a trial aimed at demonstrating non-inferiority to Eli Lilly's Tirzepatide in terms of body weight reduction [1] - The trial results indicate a setback for Novo Nordisk in the competitive obesity drug market, where Eli Lilly's Tirzepatide has shown strong performance [1] - This development may impact Novo Nordisk's market position and future growth prospects in the obesity treatment sector [1]

Core Insights - Novo Nordisk announced results from the REDEFINE 4 trial, which investigated the efficacy of CagriSema compared to tirzepatide in individuals with obesity and comorbidities [1][2] Trial Overview - REDEFINE 4 was an 84-week open-label trial involving 809 participants with a mean baseline body weight of 114.2 kg [2] - The trial compared CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) to tirzepatide (15 mg), both administered once weekly [2] Weight Loss Results - Participants treated with CagriSema achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with tirzepatide [3] - When applying the treatment-regimen estimand, CagriSema resulted in a weight loss of 20.2%, while tirzepatide achieved 23.6% [3] - The trial did not meet its primary endpoint of demonstrating non-inferiority in weight loss for CagriSema compared to tirzepatide [3] Safety Profile - CagriSema exhibited a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [4] Future Developments - Novo Nordisk is optimistic about CagriSema's potential as a first GLP-1/amylin-combination product for obesity treatment [5] - The company anticipates an FDA decision on CagriSema for weight management by late 2026, following its submission in December 2025 [5] - Upcoming trials include REDEFINE 11, expected to report data in the first half of 2027, and a higher-dose CagriSema trial planned for the second half of 2026 [5] About CagriSema - CagriSema is a once-weekly subcutaneous treatment being investigated for adults with obesity and type 2 diabetes, combining cagrilintide and semaglutide to reduce hunger and calorie intake [7] About the REDEFINE Programme - The REDEFINE programme is a phase 3 clinical development initiative that includes multiple trials assessing the efficacy and safety of CagriSema in various populations [8][9][10][11][12]

Core Insights - Novo Nordisk announced results from the REDEFINE 4 trial, which investigated the efficacy of CagriSema compared to tirzepatide in individuals with obesity and comorbidities [1][2]. Trial Overview - REDEFINE 4 was an 84-week open-label trial involving 809 participants with a mean baseline body weight of 114.2 kg, comparing CagriSema (2.4 mg cagrilintide and 2.4 mg semaglutide) to tirzepatide (15 mg) [2]. - The trial's design was open-label, meaning both investigators and participants were aware of the treatment being administered [2]. Efficacy Results - Participants treated with CagriSema achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with tirzepatide [3]. - When applying the treatment-regimen estimand, CagriSema resulted in a weight loss of 20.2%, while tirzepatide achieved 23.6% [3]. - The trial did not meet its primary endpoint of demonstrating non-inferiority in weight loss for CagriSema compared to tirzepatide [3]. Safety Profile - CagriSema exhibited a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [4]. Future Developments - The company is optimistic about CagriSema's potential as a first GLP-1/amylin-combination product for obesity treatment, with plans for further trials including REDEFINE 11 and a higher-dose trial [5]. - CagriSema was submitted to the US FDA in December 2025, with a decision expected by late 2026 [5]. - The REDEFINE 11 trial is anticipated to report data in the first half of 2027, while the higher-dose trial is set to begin in the second half of 2026 [5]. About CagriSema - CagriSema is a once-weekly subcutaneous treatment being investigated for adults with obesity and type 2 diabetes, combining cagrilintide and semaglutide to reduce hunger and increase feelings of fullness [7]. About the REDEFINE Programme - The REDEFINE programme is a phase 3 clinical development initiative that includes multiple trials aimed at assessing the efficacy and safety of CagriSema in various populations with obesity [8][9][10][11][12].

Core Insights - Novartis will present data on Rhapsido (remibrutinib), a selective oral Bruton's tyrosine kinase inhibitor, at the AAAAI Annual Meeting, focusing on its use in chronic spontaneous urticaria (CSU) and potential for peanut allergy treatment [1][2][3] Group 1: Clinical Data and Trials - New analyses from Phase III REMIX-1 and REMIX-2 trials will be presented, highlighting Rhapsido's impact on disease control and early symptom relief in CSU [2][6] - The first Phase II data on remibrutinib for IgE-mediated peanut allergy will be featured, with plans for a Phase III program in food allergy set for 2026 [2][3][6] - Positive topline results from the CIndU Phase III RemIND trial were announced, with FDA submission for symptomatic dermographism completed in Q4 2025 [4] Group 2: Regulatory and Market Potential - Regulatory reviews for remibrutinib in CSU are ongoing in regions including the European Union and Japan, indicating a strong commitment to expanding its market presence [3][4] - Novartis aims to address unmet needs in immune-mediated diseases, emphasizing the importance of innovative therapies for patients with limited alternatives [3][4] Group 3: Presentation Details - Accepted abstracts for presentation at the AAAAI include studies on the efficacy and safety of remibrutinib for peanut allergy and analyses from the REMIX studies on CSU [5][6] - Specific presentation times and formats are outlined, including oral and poster sessions scheduled from February 27 to March 1, 2026 [5][6]

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has historically done well, developing treatments for infectious diseases. Still, Barclays believes the stock a ...

Core Viewpoint - Merck's shares have increased by 46% over the past year despite facing challenges, indicating resilience in the company's performance and potential for long-term investment [1][2]. Financial Performance - The company experienced weak financial results last year, particularly due to declining revenue from its HPV vaccine franchise, Gardasil and Gardasil 9 [1]. - Merck's market capitalization stands at $303 billion, with a current stock price of $121.99 and a gross margin of 81.5% [8]. Key Products and Competition - Keytruda, Merck's leading cancer drug, is the best-selling in the world but will lose patent exclusivity by 2028, facing potential competition from new entrants like Summit Therapeutics' ivonescimab [4][6]. - Despite anticipated competition, Keytruda is expected to maintain a strong market presence due to its wide range of approved indications and proven efficacy [6]. Product Development and Pipeline - Merck has diversified its product lineup with successful approvals such as Winrevair for pulmonary arterial hypertension and Capvaxive, a pneumonia vaccine, both contributing to solid sales [8][9]. - The company is expanding its pipeline with promising candidates, including a revolutionary influenza vaccine, demonstrating its commitment to innovation and overcoming competitive pressures [9]. Dividend and Investment Outlook - Merck's dividend has increased by 93.8% over the past decade, with a payout ratio of 45.1%, indicating strong potential for future dividend increases [10]. - The stock offers a forward yield of 2.8%, significantly higher than the S&P 500 average of 1.2%, making it an attractive option for income-seeking investors [10].

Core Insights - Novartis is a major Swiss drug company with a market capitalization exceeding $300 billion, focusing on various therapeutic areas including oncology, immunology, neuroscience, and more [1][2] - The company has a strong operational history and diversified business model, making it an attractive option for conservative investors [1][2] Financial Performance - Novartis currently offers a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7% [3] - The dividend has been increasing over the past 20 years, with a payout ratio around 45%, indicating a conservative dividend profile [4] Market Challenges - The pharmaceutical industry is highly competitive and technical, with drugs facing limited patent protection, leading to revenue challenges as older drugs lose market share to generics [5] - Despite these challenges, Novartis has identified five drugs in its pipeline that are advancing or gaining new indications, which may help offset future revenue losses from patent expirations [6] Investment Perspective - Novartis is positioned as a core holding for conservative dividend investors, focusing on building a sustainable business rather than seeking high volatility [7]

Core Viewpoint - The article highlights five dividend stocks that are currently attractive for income-focused investors, particularly in light of overvalued growth stocks. Group 1: PepsiCo - PepsiCo is recommended over Coca-Cola due to its higher forward-looking dividend yield of 3.5% compared to Coke's 2.6% [4] - The company's stock has underperformed due to challenges in its food and snack business, but initiatives like healthier product options are positively impacting its financials [4] Group 2: Pfizer - Pfizer's revenue peaked at over $100 billion in 2022 due to COVID-19 but has since declined as the company focused on pandemic response [5] - The company plans to launch eight new blockbuster drugs by 2030, which could increase annual revenue from around $60 billion to $80 billion [7] - Pfizer's current dividend yield is 6.3%, making it an attractive option for income investors [8] Group 3: Realty Income - Realty Income is a REIT that has consistently paid monthly dividends since 1969 and has raised its per-share payment for over 31 years [10] - The REIT focuses on brick-and-mortar retail, with a high occupancy rate of 98.7%, indicating resilience despite challenges in the retail sector [11] Group 4: Verizon - Verizon offers a forward-looking dividend yield of 5.8% and has increased its quarterly payment for 19 consecutive years [12] - The company's strong customer dependency on mobile services supports its stable income generation [14] Group 5: IBM - IBM has a dividend yield of 2.6% and has raised its payment annually for the past 30 years [15] - A significant portion of IBM's revenue comes from high-margin software and consulting services, with annualized recurring revenue from software subscriptions at $23.6 billion [18]